Edge Therapeutics (EDGE) versus Its Competitors Financial Review

Edge Therapeutics (NASDAQ: EDGE) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Edge Therapeutics to similar businesses based on the strength of its risk, valuation, institutional ownership, profitability, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Edge Therapeutics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edge Therapeutics 0 1 1 0 2.50
Edge Therapeutics Competitors 961 3417 11919 240 2.69

Edge Therapeutics currently has a consensus target price of $25.50, suggesting a potential upside of 136.77%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.39%. Given Edge Therapeutics’ higher possible upside, research analysts plainly believe Edge Therapeutics is more favorable than its peers.

Earnings & Valuation

This table compares Edge Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Edge Therapeutics N/A -$38.82 million -6.90
Edge Therapeutics Competitors $290.27 million $35.99 million 53.45

Edge Therapeutics’ peers have higher revenue and earnings than Edge Therapeutics. Edge Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Edge Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edge Therapeutics N/A -56.88% -43.74%
Edge Therapeutics Competitors -6,417.56% -86.59% -37.07%

Insider & Institutional Ownership

50.3% of Edge Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 36.2% of Edge Therapeutics shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Edge Therapeutics peers beat Edge Therapeutics on 7 of the 12 factors compared.

About Edge Therapeutics

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply